{"analyses":[{"ciLowerLimit":"0.912","ciPctValue":"95","ciUpperLimit":"1.255","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.410","paramType":"Hazard Ratio (HR)","paramValue":"1.069","statisticalComment":"Proportional Hazards model stratified by stage of disease and size of residual disease following initial staging surgery.","statisticalMethod":"Regression, Cox"},{"ciLowerLimit":"0.746","ciPctValue":"95","ciUpperLimit":"1.039","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.131","paramType":"Hazard Ratio (HR)","paramValue":"0.880","statisticalComment":"Proportional Hazards model stratified by stage of disease and size of residual disease following initial staging surgery.","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.1","upperLimit":"45.5","value":"40.6"},{"groupId":"OG001","lowerLimit":"35.2","upperLimit":"42.1","value":"38.7"},{"groupId":"OG002","lowerLimit":"39.7","upperLimit":"49.0","value":"43.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"625"},{"groupId":"OG001","value":"625"},{"groupId":"OG002","value":"623"}],"units":"Participants"}],"description":"Median overall survival (OS)","dispersionType":"95% Confidence Interval","groups":[{"description":"Control therapy:\n\nCycles 1-6 received paclitaxel, 175 mg/m2 plus carboplatin AUC 6 plus placebo (starting in cycle 2) every 3 weeks.\n\nCycles 7-22 received placebo every 3 weeks.","id":"OG000","title":"Arm I (Placebo, Paclitaxel, Carboplatin)"},{"description":"Bevacizumab-initiation therapy:\n\nCycles 1-6 received paclitaxel, 175 mg/m2 plus carboplatin AUC 6 plus bevacizumab, 15 mg/kg (starting in cycle 2) every 3 weeks.\n\nCycles 7-22 received placebo every 3 weeks.","id":"OG001","title":"Arm II (Placebo, Paclitaxel, Carboplatin, Bevacizumab)"},{"description":"Bevacizumab-throughout therapy:\n\nCycles 1-6 received paclitaxel, 175 mg/m2 plus carboplatin AUC 6 plus bevacizumab, 15 mg/kg (starting in cycle 2) every 3 weeks.\n\nCycles 7-22 received bevacizumab, 15 mg/kg every 3 weeks.","id":"OG002","title":"Arm III (Paclitaxel, Carboplatin, Bevacizumab)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From study entry to death or last contact, up to 6 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}